



Short communication: Genetic association between schizophrenia and cannabis use



Karin J.H. Verweij^{a,b,c,*}, Abdel Abdellaoui^a, Michel G. Nivard^a, Alberto Sainz Cort^a, Lannie Ligthart^a, Harmen H.M. Draisma^{a,b}, Camelia C. Minică^a, International Cannabis Consortium¹, Nathan A. Gillespie^d, Gonneke Willemsen^a, Jouke-Jan Hottenga^a, Dorret I. Boomsma^a, Jacqueline M. Vink^{a,c}

^a Department of Biological Psychology/Netherlands Twin Register, VU University, van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands

^b Neuroscience Campus Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands

^c Behavioural Science Institute, Radboud University, Montessorilaan 3, 6525 HR Nijmegen, The Netherlands

^d Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, 800 E Leigh St, Richmond, Virginia 23219, USA

ARTICLE INFO

Article history:

Received 4 July 2016

Received in revised form

14 September 2016

Accepted 16 September 2016

Available online 10 January 2017

Keywords:

Cannabis
Schizophrenia
Polygenic risk
Genetic correlation
Quantitative genetics

ABSTRACT

Background and aim: Previous studies have shown a relationship between schizophrenia and cannabis use. As both traits are substantially heritable, a shared genetic liability could explain the association. We use two recently developed genomics methods to investigate the genetic overlap between schizophrenia and cannabis use.

Methods: Firstly, polygenic risk scores for schizophrenia were created based on summary statistics from the largest schizophrenia genome-wide association (GWA) meta-analysis to date. We analysed the association between these schizophrenia polygenic scores and multiple cannabis use phenotypes (lifetime use, regular use, age at initiation, and quantity and frequency of use) in a sample of 6,931 individuals. Secondly, we applied LD-score regression to the GWA summary statistics of schizophrenia and lifetime cannabis use to calculate the genome-wide genetic correlation.

Results: Polygenic risk scores for schizophrenia were significantly ($\alpha < 0.05$) associated with five of the eight cannabis use phenotypes, including lifetime use, regular use, and quantity of use, with risk scores explaining up to 0.5% of the variance. Associations were not significant for age at initiation of use and two measures of frequency of use analyzed in lifetime users only, potentially because of reduced power due to a smaller sample size. The LD-score regression revealed a significant genetic correlation of $r_g = 0.22$ ($SE = 0.07$, $p = 0.003$) between schizophrenia and lifetime cannabis use.

Conclusions: Common genetic variants underlying schizophrenia and lifetime cannabis use are partly overlapping. Individuals with a stronger genetic predisposition to schizophrenia are more likely to initiate cannabis use, use cannabis more regularly, and consume more cannabis over their lifetime.

© 2016 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Numerous studies have observed an association between schizophrenia and cannabis use (McGrath et al., 2010; Moore et al., 2007; Morrison et al., 2009; van Os et al., 2002), although the direction of causation is still under debate. As both traits

are substantially heritable, with heritability estimates of around 45% for lifetime cannabis use (Verweij et al., 2010) and 80% for schizophrenia (Sullivan et al., 2003), a shared genetic liability could explain the relationship. With methodological advances in molecular genetics and increased sample sizes in genome-wide association (GWA) studies it has become viable to use measured genetic variation among individuals to examine this relationship. Power et al. (2014) used results from the 2013 schizophrenia GWA study that included 13,833 schizophrenia cases and 18,310 controls (Ripke et al., 2013) to predict cannabis use in a target sample of 2082 Australian individuals. They found that the genetic variants underlying schizophrenia significantly predicted lifetime cannabis use,

* Corresponding author at: VU University, Department of Biological Psychology, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands. Tel.: +31 205985747.

E-mail addresses: karin.verweij@vu.nl, C.Verweij@bsi.ru.nl (K.J.H. Verweij).

¹ Details of the International Cannabis Consortium can be found in Appendix A.

and quantity of use within users (maximum variance explained of $R^2 = 0.47\%$ and 0.85% , respectively), but not age at initiation of cannabis use.

Here, we used two recently developed methods to further investigate the genetic covariation between both traits. Firstly we performed a polygenic risk analysis to determine the extent to which common genetic variants that affect the risk of schizophrenia predict various measures of cannabis use. Based on the results from the latest and largest schizophrenia GWA study (with up to 36,989 schizophrenia cases and 113,075 controls; [Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014](#)) we generated genetic risk scores for schizophrenia in a large independent target sample from the Netherlands. We used LDpred to create the risk score, a method shown to have greater prediction accuracy than the conventional risk prediction approach involving linkage disequilibrium (LD) pruning followed by P-value thresholding ([Vilhjalmsson et al., 2015](#)). We then determined the association of the genetic risk score for schizophrenia with various cannabis use phenotypes, including lifetime (ever versus never) use, regular use, age at initiation of use, and quantity and frequency of use.

Secondly, we applied LD-score regression to the summary statistics of the largest GWA meta-analyses of schizophrenia ([Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014](#)) and lifetime cannabis use ([Stringer et al., 2016](#)) to estimate the genome-wide genetic correlation. To our knowledge, this is the first study to determine the strength of the genetic correlation between schizophrenia and cannabis use; the information can provide useful etiological insights into the relationships between the two traits.

2. Methods

2.1. Polygenic risk prediction analysis

The target sample comprised 6,931 participants (64.1% females) from 3,244 twin families registered at the Netherlands Twin Registry ([Boomsma et al., 2006](#)). Participants were between 18 and 94 years old ($M = 43.0$, $SD = 15.7$). Data on cannabis use were obtained from five waves of self-report questionnaires sent out between 1993 and 2013 (see [Willemsen et al., 2013](#)). For subjects who participated in more than one wave we used data from their last questionnaire.

We analysed various cannabis use variables:

- 1) Lifetime cannabis use was analysed as a dichotomous variable with never users marked as 0 and ever users as 1.
- 2) Lifetime regular cannabis use (2a) was analysed as a dichotomous variable. Individuals were asked whether they had ever used cannabis regularly during their lifetime. Those who had used regularly were marked as 1 and those that had never used regularly as 0. We also repeated this analysis excluding experimental users, i.e., those that had used regularly were marked as 1 and those that had never used as 0 (2b).
- 3) Age at onset of cannabis use in years.
- 4) Lifetime frequency of use was analysed as a continuous variable (4a). Participants were asked about their lifetime frequency of cannabis use. Response categories were: 0 = never; 1 = 1–2 times; 2 = 3–5 times; 3 = 6–10 times; 4 = 11–19 times; 6 = 40 times or more. We also repeated this analysis in lifetime users only (4b).
- 5) Frequency of cannabis use was analysed as a continuous variable (5a). Participants were asked about their frequency of cannabis use during the period of heaviest use. Response categories were: 0 = never used; 1 = once a month or less often; 2 = 2–4 times a month; 3 = 2–3 times per week; 4 = 4–5 times a week; 6 = six days a week or daily. We also repeated this analysis in lifetime users only (5b).

Details of the variables, descriptives statistics and sample sizes are provided in [Table 1](#).

Genotyping was performed across five platforms and standard quality control checks were performed prior to imputation. Genotype data were imputed using the 1000 Genomes phase1 release v3 reference set. Stringent post-imputation quality thresholds were used ([Nivard et al., 2014](#)). Only single nucleotide polymorphisms (SNPs) with an imputation quality score above 0.95 were retained; SNPs were removed if they had a Minor Allele Frequency (MAF) < 0.05 or deviated from Hardy-Weinberg Equilibrium (HWE) with $p < 0.001$. Individuals were excluded if their genotype missing rate was $> 10\%$, if they had excess genome-wide homozygosity, or if they were of non-Dutch ancestry (see [Abdellaoui et al., 2013](#)). After quality control 3,622,018 SNPs remained.

Polygenic risk scores were created using LDpred ([Vilhjalmsson et al., 2015](#)), which takes into account LD among the SNPs in creating the polygenic risk scores. Risk scores in the target sample were generated by calculating the mean causal effect size of each marker using the SNP effect sizes from the latest schizophrenia GWA meta-analysis results ([Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014](#)) and the LD structure from the European populations in the 1000 Genomes reference set. We created the schizophrenia polygenic scores with the expected fraction of causal genetic variants (the fraction of markers with non-zero effects) set at 30%, because in a previous paper the risk score based on this fraction was shown to optimally predict schizophrenia (see [Vilhjalmsson et al., 2015](#)).

Generalized estimating equation (GEE) modelling was applied to test whether the polygenic risk scores for schizophrenia predicted cannabis use phenotypes in the target cohort. A covariance matrix was used to account for family relatedness and tests were based on robust (sandwich-corrected) standard error (see [Minica et al., 2014](#)). Age, sex, birth cohort (three dummy variables representing four 20-year time intervals), and ten genetic PCs (three ancestry-informative PCs and seven PCs accounting for genotyping batch effects) were included as covariates in the model. Analyses also accounted for two environmental factors (level of urbanisation and socio-economic status) that have previously been found to be associated with schizophrenia and cannabis use ([Daniel et al., 2009](#); [Kuepper et al., 2011](#); [Martino et al., 2008](#); [Vassos et al., 2012](#); [Werner et al., 2007](#)). Based on postal code, we determined the level of urbanisation of participants' residence (ranging from 1 (very high, > 2500 addresses per km^2) to 5 (very low, < 500 addresses per km^2) and socio-economic status as measured by the average income of their residential area. Variance explained by the polygenic risk scores was calculated in regression analyses as the R^2 (or Nagelkerke's pseudo- R^2 for dichotomous variables) of the model including polygenic risk scores and covariates minus the R^2 of the model including only covariates.

2.2. LD-score regression analysis

With LD-score regression ([Bulik-Sullivan et al., 2015a, 2015b](#)) the variance in a trait that can be explained by all SNPs based on GWA summary statistics is estimated. The method is based on the fact that an estimated SNP effect-size incorporates effects of all SNPs in LD with that SNP. For polygenic traits, SNPs with high LD have on average higher χ^2 statistics than SNPs with low LD (the more genetic variation a SNP tags, the higher the probability that the SNP will tag a causal variant). When regressing the χ^2 statistics from a GWA study against the LD score for each SNP, the slope of the resulting regression line provides an estimate of the proportion of trait variance accounted for by all genotyped SNPs ([Bulik-Sullivan et al., 2015b](#)). Cross-trait LD-score regression is an extension to estimate the genetic covariation between traits using GWA summary statistics of multiple traits ([Bulik-Sullivan et al., 2015a](#)). The genetic covariance is estimated using the slope from the regression of the product of z-scores from two GWA studies on the LD score. The estimate obtained from this method represents the genetic correlation between the two traits based on all polygenic effects captured by SNPs.

Here, we estimated the genetic correlation between schizophrenia and lifetime cannabis use based on the summary statistics from the largest GWA meta-analyses for schizophrenia ([Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014](#)) and cannabis use (International Cannabis Consortium, [Stringer et al., 2016](#)) to date. From the cannabis use GWA study we included only SNPs present in all contributing cohorts were included. Furthermore, we only included HapMap-3 SNPs (as suggested by [Bulik-Sullivan et al., 2015a](#)), resulting in 1,125,108 and 433,918 SNPs for schizophrenia and cannabis use, respectively. Standard LD scores were used as provided by Bulik-Sullivan and colleagues based on the 1000 genomes reference set, restricted to European populations.

3. Results

Individuals from more urbanised residential areas were more likely to have used cannabis (Nagelkerke $R^2 = 3.3\%$, $p < 0.001$), whereas socio-economic status was not associated with lifetime cannabis use ($p = 0.35$). Polygenic risk scores for schizophrenia were significantly ($\alpha < 0.05$) associated with five of the eight tested cannabis use phenotypes in the target sample, including lifetime use, regular use, and quantity of use, with risk scores explaining up to 0.5% of the variance (see [Table 1](#)). This indicates that individuals with a genetic predisposition to schizophrenia were significantly more likely to use cannabis. Associations were not significant for *Age at initiation of use*, *Lifetime frequency of cannabis use in users*, and *Frequency of use during period of most use in users*, potentially because of reduced power due to a smaller sample size for these variables.

The LD-score regression analysis revealed a significant genetic correlation of $r_g = 0.22$ ($SE = 0.07$, $p = 0.003$) between schizophrenia

Download English Version:

<https://daneshyari.com/en/article/5120204>

Download Persian Version:

<https://daneshyari.com/article/5120204>

[Daneshyari.com](https://daneshyari.com)